Uniqure Nv share price today

Name: Uniqure Nv Share Price Today (NASDAQ: QURE) - Uniqure Nv Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

(QURE)

Uniqure Nv share price is $14.91 & ₹1,291.09 as on 22 Jan 2025, 2.30 'hrs' IST

$14.91

▲

0.86

(6.12%)

Market is closed - opens 8 PM, 22 Jan 2025

View live Uniqure Nv share price in Dollar and Rupees. Guide to invest in Uniqure Nv stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Uniqure Nv, along with analyst recommendations, forecasts, and comprehensive financials.

Uniqure Nv share price movements

Today's Low: $13.75
Today's High: $15.16
$14.91
7.76%
Downside
Day's Volatility :9.3%
Upside
1.67%
52 Weeks Low: $3.73
52 Weeks High: $19.18
$14.91
74.98%
Downside
52 Weeks Volatility :80.55%
Upside
22.26%

Uniqure Nv Returns

Period	Uniqure Nv	Sector (Health Care)	Index (Russel 2000)
3 Months	118.34%	-7.4%	0.0%
6 Months	73.89%	-5.2%	0.0%
1 Year	139.97%	0.5%	0.0%
3 Years	-22.38%	8.3%	-11.0%

Uniqure Nv Key Statistics

in dollars & INR

Previous Close	$14.05
Open	$13.97
Today's High	$15.163
Today's Low	$13.7525
Market Capitalization	$750.8M
Today's Volume	$991.2K
52 Week High	$19.18
52 Week Low	$3.73
Revenue TTM	$28.6M
EBITDA	$-189.3M
Earnings Per Share (EPS)	$-4.95
Profit Margin	0.0%
Quarterly Earnings Growth YOY	-0.18%
Return On Equity TTM	-147.57%

How to invest in Uniqure Nv from India?

It is very easy for Indian residents to invest directly in Uniqure Nv from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Uniqure Nv stock in both Indian Rupees (INR) and US Dollars (USD). Search for Uniqure Nv or QURE on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Uniqure Nv or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Uniqure Nv shares which would translate to 0.058 fractional shares of Uniqure Nv as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Uniqure Nv, in just a few clicks!

Returns in Uniqure Nv for Indian investors in Rupees

Investment Value

₹1,00,000

Uniqure Nv investment value today

Current value as on today

₹2,58,599

Returns

₹1,58,599

(+158.6%)

Returns from Uniqure Nv Stock

₹1,54,437 (+154.44%)

Dollar Returns

₹4,162 (+4.16%)

Indian investors sentiment towards Uniqure Nv

-73%

Period: Oct 23, 2024 to Jan 21, 2025. Change in 30 Days versus previous period

Search volume for Uniqure Nv on INDmoney from India has reduced in the last 30 days as on Jan 22, 2025. -73% less investors are searching Uniqure Nv in the last 30 days versus the previous period.

Global Institutional Holdings in Uniqure Nv

Vestal Point Capital LP
9.74%
Nantahala Capital Management, LLC
5.71%
Boxer Capital LLC
4.56%
Millennium Management LLC
4.49%
abrdn PLC
3.96%
683 Capital Management LLC
3.80%

Analyst Recommendation on Uniqure Nv

Buy

75%Buy

25%Hold

0%Sell

Based on 20 Wall street analysts offering stock ratings for Uniqure Nv(by analysts ranked 0 to 5 stars)

Based on 20 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Uniqure Nv

What analysts predicted

Upside of 105.36%

Target:

$30.62

Current:

$14.91

Insights on Uniqure Nv

Price Movement
In the last 1 month, QURE stock has moved down by -17.3%
Decreasing Revenue
Revenue is down for the last 2 quarters, 11.12M → 2.28M (in $), with an average decrease of 79.4% per quarter
Increasing Net Profit
Netprofit is up for the last 5 quarters, -89.57M → -44.37M (in $), with an average increase of 19.3% per quarter
QURE vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 80.5% return, outperforming this stock by 102.6%

Uniqure Nv Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$11.3M	↓ 13.91%
Net Income	$-83.3M	↑ 3.63%
Net Profit Margin	-738.25%	↓ 124.92%

	FY19	Y/Y Change
Revenue	$7.3M	↓ 35.48%
Net Income	$-128.0M	↑ 53.67%
Net Profit Margin	-1.8K%	↓ 1019.9%

	FY20	Y/Y Change
Revenue	$37.5M	↑ 415.23%
Net Income	$-125.0M	↓ 2.33%
Net Profit Margin	-333.27%	↑ 1424.88%

	FY21	Y/Y Change
Revenue	$524.0M	↑ 1296.82%
Net Income	$329.6M	↓ 363.62%
Net Profit Margin	62.9%	↑ 396.17%

	FY22	Y/Y Change
Revenue	$106.5M	↓ 79.68%
Net Income	$-126.8M	↓ 138.47%
Net Profit Margin	-119.07%	↓ 181.97%

	FY23	Y/Y Change
Revenue	$15.8M	↓ 85.12%
Net Income	$-308.5M	↑ 143.3%
Net Profit Margin	-1.9K%	↓ 1828.02%

	Q2 FY23	Q/Q Change
Revenue	$2.4M	↓ 54.52%
Net Income	$-68.5M	↓ 11.33%
Net Profit Margin	-2.8K%	↓ 1376.9%

	Q3 FY23	Q/Q Change
Revenue	$1.4M	↓ 41.91%
Net Income	$-89.6M	↑ 30.81%
Net Profit Margin	-6.4K%	↓ 3538.93%

	Q4 FY23	Q/Q Change
Revenue	$6.7M	↑ 375.41%
Net Income	$-73.2M	↓ 18.27%
Net Profit Margin	-1.1K%	↑ 5271.68%

	Q1 FY24	Q/Q Change
Revenue	$8.5M	↑ 26.85%
Net Income	$-65.6M	↓ 10.37%
Net Profit Margin	-773.34%	↑ 321.08%

	Q2 FY24	Q/Q Change
Revenue	$11.1M	↑ 31.13%
Net Income	$-56.3M	↓ 14.2%
Net Profit Margin	-506.01%	↑ 267.33%

	Q3 FY24	Q/Q Change
Revenue	$2.3M	↓ 79.44%
Net Income	$-44.4M	↓ 21.17%
Net Profit Margin	-1.9K%	↓ 1434.44%

	FY18	Y/Y Change
Profit	$11.3M	↓ 13.91%

	FY19	Y/Y Change
Profit	$-87.5M	↓ 875.04%

	FY20	Y/Y Change
Profit	$-84.9M	↓ 2.94%

	FY21	Y/Y Change
Profit	$499.0M	↓ 687.88%

	FY22	Y/Y Change
Profit	$103.1M	↓ 79.33%

	FY23	Y/Y Change
Profit	$2.2M	↓ 97.85%

	Q2 FY23	Q/Q Change
Profit	$1.1M	↓ 62.98%

	Q3 FY23	Q/Q Change
Profit	$401.0K	↓ 62.52%

	Q4 FY23	Q/Q Change
Profit	$-2.1M	↓ 635.16%

	Q1 FY24	Q/Q Change
Profit	$-3.4M	↑ 57.04%

	Q2 FY24	Q/Q Change
Profit	$995.0K	↓ 129.53%

	Q3 FY24	Q/Q Change
Profit	$1.3M	↑ 27.24%

	FY18	Y/Y Change
Operating Cash Flow	$-76.0M	↑ 18.31%
Investing Cash Flow	$-4.2M	↓ 23.97%
Financing Cash Flow	$158.0M	↑ 75.37%

	FY19	Y/Y Change
Operating Cash Flow	$-98.7M	↑ 29.78%
Investing Cash Flow	$-6.6M	↑ 56.58%
Financing Cash Flow	$248.8M	↑ 57.52%

	FY20	Y/Y Change
Operating Cash Flow	$-134.8M	↑ 36.63%
Investing Cash Flow	$-9.5M	↑ 42.68%
Financing Cash Flow	$7.4M	↓ 97.01%

	FY21	Y/Y Change
Operating Cash Flow	$288.0M	↓ 313.58%
Investing Cash Flow	$-67.4M	↑ 610.53%
Financing Cash Flow	$94.9M	↑ 1174.29%

	FY22	Y/Y Change
Operating Cash Flow	$-145.1M	↓ 150.38%
Investing Cash Flow	$-182.7M	↑ 171.17%
Financing Cash Flow	$1.4M	↓ 98.48%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-57.0M	↓ 27.21%
Investing Cash Flow	$45.8M	↑ 1433.8%
Financing Cash Flow	$370.1M	↑ 282447.33%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$38.9M	↓ 168.27%
Investing Cash Flow	$-314.1M	↓ 785.28%
Financing Cash Flow	$-7.6M	↓ 102.05%

Uniqure Nv Technicals Summary

Sell

Neutral

Buy

Uniqure Nv is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Uniqure Nv Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Uniqure Nv	-19.39%	73.89%	139.97%	-22.38%	-77.39%
Biontech Se	-1.39%	34.63%	11.61%	-25.86%	219.89%
Regeneron Pharmaceuticals, Inc.	-4.69%	-35.75%	-28.6%	9.67%	97.4%
Vertex Pharmaceuticals Incorporated	4.13%	-14.02%	-4.03%	83.73%	84.23%
Alnylam Pharmaceuticals, Inc.	1.66%	4.14%	29.82%	80.38%	105.23%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Uniqure Nv	2.64	NA	0.0	-3.73	-1.48	-0.17	NA	1.15
Biontech Se	160.8	NA	0.04	-3.34	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	16.86	16.86	1.05	44.99	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.1	0.48	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Uniqure Nv	Buy	$750.8M	-77.39%	2.64	0.0%
Biontech Se	Buy	$26.8B	219.89%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$74.9B	97.4%	16.86	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$108.7B	84.23%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$31.8B	105.23%	NA	-15.86%

About Uniqure Nv

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Organization	Uniqure Nv
Employees	480
CEO	Mr. Matthew Craig Kapusta CPA
Industry	Health Technology

Management People of Uniqure Nv

Name	Title
Mr. Matthew Craig Kapusta CPA	CEO & Executive Director
Mr. Christian Klemt	CFO, Principal Financial Officer & GM of Amsterdam Site
Mr. Richard Porter Ph.D.	Chief Business & Scientific Officer
Dr. Jeannette Potts J.D., Ph.D.	Chief Legal & Compliance Officer and Corporate Secretary
Prof. Hugo Katus	Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
Dr. Amin Abujoub Ph.D.	Chief Technical Operations
Dr. Tamara Tugal Ph.D., MBA	Business Development Director
Ms. Erin Boyer	Chief People & Culture Officer
Dr. Walid Abi-Saab M.D.	Chief Medical Officer
Eileen Sawyer	Vice President of Global Medical Affairs

Important FAQs about investing in Uniqure Nv from India :

What is Uniqure Nv share price today?

Uniqure Nv share price today stands at $14.91, Open: $13.97 ; Previous Close: $14.05 ; High: $15.16 ; Low: $13.75 ; 52 Week High: $19.18 ; 52 Week Low: $3.73. The stock opens at $13.97, after a previous close of $14.05. The stock reached a daily high of $15.16 and a low of $13.75, with a 52-week high of $19.18 and a 52-week low of $3.73.

Can Indians buy Uniqure Nv shares?

Yes, Indians can invest in the Uniqure Nv (QURE) from India.

With INDmoney, you can buy Uniqure Nv at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Uniqure Nv at zero transaction cost.

How can I buy Uniqure Nv shares from India?

It is very easy to buy Uniqure Nv from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Uniqure Nv be purchased?

Yes, you can buy fractional shares of Uniqure Nv with INDmoney app.

What are the documents required to start investing in Uniqure Nv stocks?

To start investing in Uniqure Nv, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.